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Abstract
Background:  Although the methods for conducting systematic reviews of efficacy are well
established, there is much less guidance on how systematic reviews of adverse effects should be
performed.
Methods: In order to determine where methodological research is most needed to improve
systematic reviews of adverse effects of health care interventions, we conducted a descriptive
analysis of systematic reviews published between 1994 and 2005. We searched the Database of
Abstracts of Reviews of Effects (DARE) and The Cochrane Database of Systematic Reviews
(CDSR) to identify systematic reviews in which the primary outcome was an adverse effect or
effects. We then extracted data on many of the elements of the systematic review process
including: types of interventions studied, adverse effects of interest, resources searched, search
strategies, data sources included in reviews, quality assessment of primary data, nature of the data
analysis, and source of funding.
Results:  256 reviews were included in our analysis, of which the majority evaluated drug
interventions and pre-specified the adverse effect or effects of interest. A median of 3 resources
were searched for each review and very few reviews (13/256) provided sufficient information to
reproduce their search strategies. Although more than three quarters (185/243) of the reviews
sought to include data from sources other than randomised controlled trials, fewer than half (106/
256) assessed the quality of the studies that were included. Data were pooled quantitatively in most
of the reviews (165/256) but heterogeneity was not always considered. Less than half (123/256) of
the reviews reported on the source of funding.
Conclusion: There is an obvious need to improve the methodology and reporting of systematic
reviews of adverse effects. The methodology around identification and quality assessment of
primary data is the main concern.
Background
While the assessment of adverse effects in systematic
reviews of health care interventions is undoubtedly essen-
tial, there are significant methodological challenges in
undertaking such reviews [1,2]. Some guidance is availa-
ble from The Cochrane Collaboration [3] but the lack of
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empirical knowledge remains a major handicap to review-
ers. The difficulty of sensitive searching in MEDLINE and
EMBASE has already been identified [4-6], and there is
still considerable uncertainty over the type and quality of
studies that should be included in these systematic
reviews. A closer look at the content and methods of pub-
lished reviews is needed to identify priority areas for
methodological research.
Our aim was to describe the general characteristics of sys-
tematic reviews published from 1994 to 2005 that
focussed primarily on adverse outcomes associated with
healthcare interventions, in order to identify priority areas
for methodological research. The decision to begin by
looking at systematic reviews with adverse effects as the
primary outcome was a pragmatic one.
Methods
We searched The Cochrane Database of Systematic
Reviews (CDSR) and the Database of Abstracts of Reviews
of Effects (DARE) via The Cochrane Library, plus DARE
via the Centre for Reviews and Dissemination (CRD) web-
site [see Additional file 1]. These databases were chosen
because they are major, comprehensive collections of sys-
tematic reviews. For instance, DARE is compiled through
rigorous monthly searches of bibliographic databases
(including MEDLINE and EMBASE) as well as hand-
searching of key journals, grey literature and regular
searches of the internet. We did not place any language
restrictions on the searches and we aimed to retrieve sys-
tematic reviews published from 1994 onwards.
Two researchers independently screened titles and
abstracts and selected full papers for inclusion. Any dis-
crepancies between the researchers were resolved by dis-
cussion and consensus. A review was included if the
primary aim was to evaluate adverse effects, known to be,
or suspected to be, associated with an intervention. This
was regardless of whether the review's hypothesis stated
that the intervention increased or reduced the outcome.
Papers that investigated the complete safety profile of an
intervention were included if this was their primary aim.
We abstracted pre-defined descriptive data using a stand-
ardised form designed for this study. For each review, we
collected baseline data on the types of intervention
Summary of systematic review identification, retrieval and inclusion/exclusion Figure 1
Summary of systematic review identification, retrieval and inclusion/exclusion.
Title and abstracts identified
and screened, n = 3635 
Full copies ordered and received, n=298 
Excluded, n=41 
Prevention of adverse effect, n =1 
Adverse effect is secondary outcome, n=18 
Methodology paper, n=1 
Treatment of adverse effect, n = 3 
Clinical effectiveness, n=16
Drop out/ Discontinuation rates, n = 1 
Overdose, n = 1 
Publications meeting the inclusion criteria
and included in the review, n = 257 
Total number of Cochrane systematic reviews, n = 11 
Total number of DARE systematic reviews, n =246 BMC Medical Research Methodology 2006, 6:3 http://www.biomedcentral.com/1471-2288/6/3
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reviewed, scope of the adverse effects evaluation, and the
source of funding. We then looked at specific methodo-
logical issues which were raised in the Cochrane Hand-
book guidance. This covered the topics of search strategy,
resources searched, types of studies reviewed, quality
assessment, and data analysis.
Results
From 3635 titles and abstracts screened, 298 full reports
were retrieved and 256 reviews met our inclusion criteria
[see Figure 1]. Most of the included reviews were identi-
fied from DARE with only 11 Cochrane reviews identified
from CDSR. The number of reviews focusing on adverse
effects is increasing over time but the proportion of these
reviews relative to all reviews on DARE has remained
between 2% and 8% [see Figure 2].
Types of interventions studied
The included reviews are dominated by those evaluating
the adverse effects of drugs (64%), with only a few studies
looking at surgical procedures (8%) or other physical
interventions such as acupuncture (5%) [see Table 1]. The
most commonly reviewed drugs were female hormonal
agents used either as replacement therapy (24 reviews) or
as contraception (14 reviews).
Scope of adverse effects evaluation
Rather than investigating all potential adverse effects,
80% (208/256) of the reviews preferred to focus on pre-
specified adverse effects outcomes.
Sources of funding
Less than half of the reviews (123/256) provided informa-
tion on the source of funding. Of the reviews that did
report financial support 85 were independent sources, 32
could represent a conflict of interest (largely a drug man-
ufacturer), and 6 said they received no financial support.
Resources searched
Nearly all of the reviews (250/256) listed the resources
searched to identify studies. The median number of elec-
tronic databases searched was only 2 (range 0 to 25),
MEDLINE being the most popular (242/256) followed by
EMBASE (90/256). Many reviews (218/256) reported
searching at least one additional source with the refer-
Proportion of systematic reviews of adverse effects relative  to all reviews on DARE by year of publication Figure 2
Proportion of systematic reviews of adverse effects rela-
tive to all reviews on DARE by year of publication. The 
results shown for 2004, and to a lesser extent 2003, are low 
because some records are still in the DARE production proc-
ess.
Systematic Reviews on DARE
0
100
200
300
400
500
600
700
800
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
Year of Publication
N
o
.
 
o
f
 
R
e
v
i
e
w
s
All Reviews
Reviews of Adverse
Effects
Table 1: Number of reviews by type of intervention
Year of 
publication
Type of intervention Total number of 
reviews
Drug Surgical/dental Physical Diagnostic/
screening
Other
1994 500005
1995 90003 1 2
1996 96205 2 1
1997 1 5 2106 2 9
1998 1 8 2004 2 3
1999 2 1 1014 2 7
2000 1 3 2102 1 7
2001 1 7 1209 2 7
2002 19 7 3 0 11 40
2003 26 1 3 0 14 44
2004 1 2 1103 1 7
Jan-Apr 2005 000000
Total 164 20 13 1 56 256
The sum of reviews by intervention is greater than the total number of reviews because 5 reviews examined 2 (4 reviews) or 3 (1 review) types of 
intervention (e.g. drug and non-drug antihypertensive therapy)BMC Medical Research Methodology 2006, 6:3 http://www.biomedcentral.com/1471-2288/6/3
Page 4 of 6
(page number not for citation purposes)
ences from included studies being by far the most popular
(199/256), followed by contacting experts in the field
(58/256).
Search strategies
The authors reported their search strategies in three quar-
ters (196/256) of the reviews, but very few (13/256) pro-
vided sufficient information to reproduce the search.
Almost half of the reproducible searches were conducted
by a qualified information specialist (6/13) compared to
only 7% (17/243) of those that did not report enough
detail. In most cases (165/256) it was unclear whether the
searches had been restricted by language; only 15% (38/
256) explicitly restricted by language and 21% (53/256)
explicitly did not.
Even when search strategies were reported they were
invariably limited. Many did not use any synonyms (149/
196) or truncation (171/196). Of those that indicated
which fields were searched almost half (20/43) relied
solely on indexing or solely on text words.
Data sources included in reviews
About 5% (13/256) of reviews did not report on the types
of studies included in their analysis. While 63% (154/
243) of the remaining reviews sought to include studies
that compared the intervention with a control, only 28%
(68/243) of reviews limited themselves to data from ran-
domised controlled trials (RCTs). Cohort studies (75/
243) and case-control studies (67/243) were included in
about one third of the reviews whereas case series (21/
243) and case reports (28/243) were included in approxi-
mately 10%.
Quality assessment of primary data
Less than half (106/256) of the reviews specified assess-
ment of the quality of the included studies in the methods
section, or alluded to it by describing in the methods data
extraction that included indicators of study quality. Forty-
nine of the 106 reviews used existing quality assessment
instruments, mostly to assess RCTs. Although some of the
reviews evaluated data from a variety of study designs, evi-
dence hierarchies were rarely used (12/256).
Nature of the data analysis
Meta-analysis was used to pool data in over 60% (165/
256) of the reviews and almost 90% (145/165) of those
reviews assessed heterogeneity. In 10% (27/256) of the
reviews, overall event rates were derived by simply adding
up the numbers of events reported in each of the included
studies and only 37% (10/27) of those reviews considered
heterogeneity. Sixty-four reviews presented only narrative
synthesis; 20/64 gave reasons for not pooling data quan-
titatively. Heterogeneity was the most common reason
given (12/20).
Discussion
Our interest lies in the methods of addressing adverse
effects in systematic reviews. Our finding that this type of
review accounts for approximately 4% of systematic
reviews is consistent with an earlier survey of reviews on
The Cochrane Library and MEDLINE [7]. There are several
findings regarding the nature and methodology of the sys-
tematic reviews of adverse effects that merit further discus-
sion.
Types of interventions studied
One area of concern is that systematic reviews identified
in this study have mainly been directed towards the
adverse effects of pharmacological interventions. This
emphasis on drug therapy needs to be redressed, given
that surgical and other physical interventions are widely
used in healthcare, and may have equally important or
serious adverse effects.
Scope of adverse effects evaluation
Many of the reviews also tended to be directed towards
evaluating pre-specified adverse outcomes of interest,
which indicates that the reviewers usually had an a priori
hypothesis when conducting the review and that the
detection of new unrecognised adverse effects was of
lesser interest. It may also reflect the relative ease of con-
centrating on a few major outcomes rather than spreading
oneself too wide. Indeed this mirrors the experience of
researchers who have argued that the focused approach is
better able to yield clinically relevant results [8] than
broad, unfocused reviews.
Sources of funding
Under reporting of the source of funding is evident from
our findings. Source of funding is obviously important as
it may be in the manufacturer's interest to highlight the
positive safety aspects of their product. Missing data on
funding meant we could not conduct subgroup analysis
with confidence to investigate whether the conclusions of
manufacturer-sponsored reviews differed from independ-
ently or non-sponsored studies. Other researchers have
found that trials funded by drug companies are more
likely to have outcomes that favour the sponsor's product
[9]. It is possible that a similar bias exists in some system-
atic reviews of adverse effects, where the review may
downplay any safety concerns. Here, we urge systematic
reviewers to disclose their source of funding and any com-
peting interests. We also recommend further research into
how the analysis and reporting of adverse effects may or
may not vary with the source of funding.
Resources searched
The number of sources searched was low and even lower
than reported in a similar study of systematic reviews of
qualitative data [Booth A. ISSG Meeting 2005]. Not sur-BMC Medical Research Methodology 2006, 6:3 http://www.biomedcentral.com/1471-2288/6/3
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prisingly, as with reviews of efficacy, nearly all the reviews
here searched MEDLINE. This is most likely due to acces-
sibility and popularity rather than the usefulness of
MEDLINE as a source of information on adverse effects.
For example, EMBASE is likely to be a better source of
information on drug-related adverse effects than
MEDLINE [5]. We recommend that reviewers adopt more
comprehensive searches across a wider range of sources.
Researchers who are not familiar with the differing con-
tent of databases may end up relying too heavily on
MEDLINE, and there is a need for research and guidance
into prioritizing the most useful databases when search-
ing for information on adverse effects.
Search strategies
The set of reviews described here provided only limited
information on the techniques they employed to identify
primary studies and the search strategies that were
reported tended to be of poor quality. Synonyms, trunca-
tion and the use of text words in combination with index-
ing were rarely used, yet these are all crucial aspects of a
sensitive search strategy as required by systematic reviews.
We believe that search strategies should be reported more
clearly and that it may be more appropriate to use broader
search strategies when searching for studies for a system-
atic review.
Data sources included in reviews
It was interesting to find that substantial numbers of
reviews chose to extend their analysis beyond data from
controlled trials, and into the realms of observational
studies. This probably stems from the widely held view
that short-term trials in selected populations are not the
best study design for the evaluation of rare or long-term
adverse effects, and that reviewers may find it necessary to
utilize other data sources.
Quality assessment of primary data
The areas of quality assessment and data analysis are of
some concern here. It is difficult to judge the reliability of
the primary data, given that less than half the reviews
reported any attempt to assess quality. This may be
explained by the absence of a defined quality assessment
tool, especially with regards to observational studies.
Moreover, the evidence hierarchies that are often used in
the evaluation of clinical efficacy may not be appropriate
for adverse effects information, and there is a need to
develop appropriate ways of assessing quality of adverse
effects data from different types of studies.
Nature of the data analysis
It is clear from our data that there are many occasions
where meta-analysis is not the analytic method of choice,
and this may reflect the problems with handling diverse
sources of data. On the other hand, some reviewers who
pool data appear to disregard differences between the
studies. There is a clear need for further research and guid-
ance into the appropriate methods of synthesizing data
that arise from a wide range of study designs.
Limitations of our analysis
DARE and CDSR were awkward to search for the type of
reviews we were interested in and it is possible that we
missed some relevant reviews. It is not possible to search
using floating subheadings in DARE via the CRD inter-
face, or to limit the search to the 'outcomes' field in DARE
via The Cochrane Library interface, or to limit the search
to the 'objectives' section in Cochrane review abstracts on
CDSR. Our sample of reviews will also have been influ-
enced by changes in the production of DARE over time,
including more sensitive searches to identify systematic
reviews and tighter criteria for inclusion of reviews on the
database. Only 5/256 reviews in our sample were non-
English language publications, which may not be a fair
representation because CDSR only has English language
reviews and translation capacity delays some foreign lan-
guage reviews reaching DARE.
Although this systematic review was limited to reviews in
which adverse effects were a primary outcome, much of
the methodology should be relevant to systematic reviews
in which adverse effects are secondary outcomes. Such
reviews will often require additional searches to those for
the clinical effects, which are often limited to RCTs. Simi-
larly, there are issues surrounding quality assessment and
the pooling of data from different data sources. It would
be very useful to survey the methods of assessing adverse
effects data in systematic reviews where adverse effects
have been considered to be a secondary aim, and to com-
pare those findings against ours.
Conclusion
Two areas of methodology that should be prioritised for
improvement are searching and quality assessment.
Although questions on the optimal search strategies
remain to be answered, the basic quality of searching
could easily be improved by more involvement from an
information specialist. Future research could be under-
taken to investigate how the deficiencies in the searches
identified here could alter the conclusions of a review.
This could be done by case studies in which the yield and
consequent findings from more comprehensive searches
are compared to basic searching.
The lack of a defined and empirically tested quality assess-
ment tool is a major problem. In order to be able to form
reliable conclusions, readers of systematic reviews need to
have some indication of the reliability and validity of the
primary adverse effects data. The development of this
quality instrument could be mirrored on the model suc-Publish with BioMed Central    and   every 
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cessfully used in producing the tool for the quality assess-
ment of studies of diagnostic accuracy [10].
There is also undoubtedly a need to improve the quality
of reporting. Incomplete reporting might partly be due to
limited space in journal articles, but space is often wasted
on vague or ambiguous reporting that is particularly
noticeable in the reporting of search strategies. It is impor-
tant that guidelines on the reporting of systematic reviews
continue to incorporate evidence of actual reporting defi-
ciencies from published reviews of adverse effects [11,12].
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